Huyang Xie

5PUBLICATIONS
5CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Computational physiologyCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 16, 2026
Mendelian Randomization Identified SLC2A9 as a Novel cis-eQTL-Mediated Susceptibility Gene in Suppressing Renal Cancer and Its Related Metabolic Mechanisms.

Yi Wang, Yu Song, Hao Ji

|Nov 06, 2018
Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.

Zheng Liu, Yu Zhu, Le Xu

|Apr 14, 2018
Author Correction: The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma.

Fujiang Xu, Kun Chang, Jian Ma

|Mar 09, 2018
Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.

Hangcheng Fu, Yu Zhu, Yiwei Wang

|Aug 31, 2017
The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma.

Fujiang Xu, Kun Chang, Jian Ma

Pageof 1

Frequent Collaborators

2 joint publications

Jiejie Xu

1 joint publications

Yi Wang

1 joint publications

Yu Song

1 joint publications

Hao Ji